Molecular Medicine

, Volume 13, Issue 1–2, pp 97–104 | Cite as

Hepcidin Expression in the Liver: Relatively Low Level in Patients with Chronic Hepatitis C

  • Naoki Fujita
  • Ryosuke Sugimoto
  • Masaki Takeo
  • Naohito Urawa
  • Rumi Mifuji
  • Hideaki Tanaka
  • Yoshinao Kobayashi
  • Motoh Iwasa
  • Shozo Watanabe
  • Yukihiko Adachi
  • Masahiko Kaito
Research Article


Patients with chronic hepatitis C frequently have serum and hepatic iron overload, but the mechanism is unknown. Recently identified hepcidin, exclusively synthesized in the liver, is thought to be a key regulator for iron homeostasis and is induced by infection and inflammation. This study was conducted to determine the hepatic hepcidin expression levels in patients with various liver diseases. We investigated hepcidin mRNA levels of liver samples by real-time detection-polymerase chain reaction; 56 were hepatitis C virus (HCV) positive, 34 were hepatitis B virus (HBV) positive, and 42 were negative for HCV and HBV (3 cases of autoimmune hepatitis, 7 alcoholic liver disease, 13 primary biliary cirrhosis, 9 nonalcoholic fatty liver disease, and 10 normal liver). We analyzed the relation of hepcidin to clinical, hematological, histological, and etiological findings. Hepcidin expression levels were strongly correlated with serum ferritin (P < 0.0001) and the degree of iron deposit in liver tissues (P < 0.0001). Hepcidin was also correlated with hematological parameters (vs. hemoglobin, P = 0.0073; vs. serum iron, P = 0.0012; vs. transferrin saturation, P < 0.0001) and transaminase levels (P = 0.0013). The hepcidin-to-ferritin ratio was significantly lower in HCV+ patients than in HBV+ patients (P = 0.0129) or control subjects (P = 0.0080). In conclusion, hepcidin expression levels in chronic liver diseases were strongly correlated with either the serum ferritin concentration or degree of iron deposits in the liver. When adjusted by either serum ferritin values or hepatic iron scores, hepcidin indices were significantly lower in HCV+ patients than in HBV+ patients, suggesting that hepcidin may play a pivotal role in the pathogenesis of iron overload in patients with chronic hepatitis C.



This study was supported by a grant-in-aid (no. 18590728, 2006-2007) from the Ministry of Education, Science and Culture of Japan.


  1. 1.
    Hentze MW, Muckenthaler MU, Andrews NC. (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117:285–97.CrossRefGoogle Scholar
  2. 2.
    Nicoras G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. (2002) Hepcidin, a new iron regulatory peptide. Blood Cells Mol. Dis. 29:327–35.CrossRefGoogle Scholar
  3. 3.
    Ganz T. (2003) Hepcidin: a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783–8.CrossRefGoogle Scholar
  4. 4.
    Nemeth E et al. (2004) Hepcidin regulates iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–3.CrossRefGoogle Scholar
  5. 5.
    Nicolas G et al. (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110:1037–44.CrossRefGoogle Scholar
  6. 6.
    Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113:1271–6.CrossRefGoogle Scholar
  7. 7.
    Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. (1992) Measurements of iron status in patients with chronic hepatitis. Gastroenterology 102:2108–13.CrossRefGoogle Scholar
  8. 8.
    Boucher E, Bourienne A, Adams P, Turlin B, Brissot B, Deugnier Y. (1997) Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 41:115–20.CrossRefGoogle Scholar
  9. 9.
    Metwally MA, Zein CO, Zein NN. (2004) Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am. J. Gastroenterol. 99:286–91.CrossRefGoogle Scholar
  10. 10.
    Tharburn D et al. (2002) The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 50:248–52.CrossRefGoogle Scholar
  11. 11.
    Tung BY, Emond MJ, Bromer MP, Raaka SD, Cotler SJ, Kowdley KV. (2003) Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 124:318–26.CrossRefGoogle Scholar
  12. 12.
    Bassett SE et al. (1999) Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology 29:1884–92.CrossRefGoogle Scholar
  13. 13.
    Olynyk JK et al. (1995) Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 108:1104–9.CrossRefGoogle Scholar
  14. 14.
    Souza RM, Freitas LAR, Lyra AC, Moraes CF, Braga EL, Lyra LGC. (2006) Effect of iron overload on the severity of liver histologic alterations and on the response to interferon and ribavirin therapy of patients with hepatitis C infection. Braz. J. Med. Biol. Res. 39:79–83.CrossRefGoogle Scholar
  15. 15.
    Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF, Koeffler HP. (1999) Molecular cloning of transferrin receptor 2: a new member of the transferrin receptor-like family. J. Biol. Chem. 274:20826–32.CrossRefGoogle Scholar
  16. 16.
    Takeo M, Kobayashi Y, Fujita N, et al. (2005) Up-regulation of transferrin receptor 2 and ferroportin 1 mRNA in the liver of patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 20: 562–9.CrossRefGoogle Scholar
  17. 17.
    Kawabata H, Germain RS, Vuong PT, Nakamaki T, Said JW, Koeffler HP. (2000) Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo. J. Biol. Chem. 275:16618–25.CrossRefGoogle Scholar
  18. 18.
    Fleming RE et al. (2000) Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc. Natl. Acad. Sci. U. S. A. 97:2214–9.CrossRefGoogle Scholar
  19. 19.
    Camaschella C et al. (2000) The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat. Genet. 25:14–5.CrossRefGoogle Scholar
  20. 20.
    Roetto A et al. (2001) New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 97:2555–60.CrossRefGoogle Scholar
  21. 21.
    Kawabata H et al. (2005) Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 105:376–81.CrossRefGoogle Scholar
  22. 22.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–20.CrossRefGoogle Scholar
  23. 23.
    Deugnier YM et al. (1992) Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 102:2050–9.CrossRefGoogle Scholar
  24. 24.
    Deugnier YM et al. (1993) Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 cases. Hepatology 17:30–4.CrossRefGoogle Scholar
  25. 25.
    Silvia TSS et al. (2005) Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study. J. Gastroenterol. Hepatol. 20:243–8.CrossRefGoogle Scholar
  26. 26.
    Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. (2001) A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 276:7811–9.CrossRefGoogle Scholar
  27. 27.
    Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. (2000) LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480:147–50.CrossRefGoogle Scholar
  28. 28.
    Park CH, Valore EV, Waring AJ, Ganz T. (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276:7806–10.CrossRefGoogle Scholar
  29. 29.
    Nicolas G, Beennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S. (2001) Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98:8780–5.CrossRefGoogle Scholar
  30. 30.
    Nicolas G et al. (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc. Natl. Acad. Sci. U. S. A. 99:4596–601.CrossRefGoogle Scholar
  31. 31.
    Roetto A et al. (2003) Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat. Genet. 33:21–2.CrossRefGoogle Scholar
  32. 32.
    Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, Mckie AT, Trinder D, Anderson GJ. (2002) Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 123:835–44.CrossRefGoogle Scholar
  33. 33.
    Lee P, Peng H, Gelbart T, Beutler E. (2004) The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta2-microglobulin-deficient hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 101:9263–5.CrossRefGoogle Scholar
  34. 34.
    Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. (2005) Hepcidin is decreased in TfR2-hemochromatosis. Blood 105:1803–6.CrossRefGoogle Scholar
  35. 35.
    Montosi G et al. (2005) Kuppfer cells and macrophages are not required for hepatic hepcidin activation during iron overload. Hepatology 41:545–52.CrossRefGoogle Scholar
  36. 36.
    Kobune M, Kohgo Y, Kato J, Miyazaki E, Niitsu Y. (1994) Interleukin-6 enhances hepatic transferrin uptake, and ferritin expression in rats. Hepatology 19:1468–75.CrossRefGoogle Scholar
  37. 37.
    Ahmad KA et al. (2002) Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cell Mol. Dis. 29:361–6.CrossRefGoogle Scholar
  38. 38.
    Bridle KR et al. (2003) Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 361:669–73.CrossRefGoogle Scholar
  39. 39.
    Pietrangelo A. (2005) Non-HFE hemochromatosis. Semin. Liver Dis. 25:450–60.CrossRefGoogle Scholar
  40. 40.
    Sohda T, Okubo R, Kamimura S, Ohkawara T. (2001) Hemochromatosis with HFE gene mutation in a Japanese patient. Am. J. Gastroenterol. 96:2487–8.CrossRefGoogle Scholar
  41. 41.
    Koyama C et al. (2005) Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Hematologica 90:302–7.Google Scholar
  42. 42.
    Koyama C et al. (2005) Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J. Hepatol. 43: 740–2.CrossRefGoogle Scholar
  43. 43.
    Koyama C et al. (2005) A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron. Intern. Med. 44:990–3.CrossRefGoogle Scholar
  44. 44.
    Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL. (2005) Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J. Clin. Gastroenterol. 39:71–4.PubMedGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2007

Authors and Affiliations

  • Naoki Fujita
    • 1
  • Ryosuke Sugimoto
    • 1
  • Masaki Takeo
    • 1
  • Naohito Urawa
    • 1
  • Rumi Mifuji
    • 1
  • Hideaki Tanaka
    • 1
  • Yoshinao Kobayashi
    • 1
  • Motoh Iwasa
    • 1
  • Shozo Watanabe
    • 2
  • Yukihiko Adachi
    • 1
  • Masahiko Kaito
    • 1
  1. 1.Department of Gastroenterology and Hepatology, Division of Clinical Medicine and Biomedical Science, Institute of Medical ScienceMie University Graduate School of MedicineMieJapan
  2. 2.Health Administration CenterMie UniversityMieJapan

Personalised recommendations